Showing results (71-80 of 79) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Neurology(R) Neuroimmunology & Neuroinflammation|September 22, 2019
Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides: Insights from the DCVAS studyAntje Bischof, Veronika K Jaeger, Robert D M Hadden, et al.Iscience|February 28, 2024
Coordinated metabolic responses to cyclophilin D deletion in the developing heartGisela Beutner, Jonathan Ryan Burris, Michael P Collins, et al.Cardiology Research|January 8, 2024
The Heart of Rett Syndrome: A Quantitative Analysis of Cardiac RepolarizationMichael P Collins, Mark C Johnson, Robin C Ryther, et al.Plos One|May 12, 2011
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expressionLiang Zhang, Manoj Bhasin, Rachel Schor-Bardach, et al.Journal of the Peripheral Nervous System : JPNS|November 3, 2010
Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summaryMichael P Collins, P James B Dyck, Gary S Gronseth, et al.Journal of Neuropathology and Experimental Neurology|November 9, 2025
Establishment of normal myofiber size distribution in children and young adultsMichael W Lawlor, Marta Margeta, Karra A Jones, et al.Journal of Medicinal Chemistry|September 9, 2011
Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agentMaria-Elena Theoclitou, Brian Aquila, Michael H Block, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient TumorsJ Andrew Livingston, Jean-Yves Blay, Jonathan Trent, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid MalignanciesCourtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, et al.Pageof 8